top of page

Arcellx’s CMO gives an update on their BCMA program at the 2023 CAR-TCR Summit

Aug 30, 2023

1 min read

Chris Heery describes the process relating to bridging therapy that enabled a partial clinical hold to lift.

https://vimeo.com/859461507?share=copy

Recent Posts

Oxford based Alethio Therapeutics unveiled a $90M Series A today to advance its therapies for myeloproliferative neoplasms, and also announced for the first time that ATX-011's target will be G6B

Oxford based Alethio Therapeutics unveiled a $90M Series A today to advance its therapies for myeloproliferative neoplasms, and also announced for the first time that ATX-011's target will be G6B

From Montreal: Ocythera is developing a treatment for rare bone disorders that targets the retinoic acid pathway without using retinoids

From Montreal: Ocythera is developing a treatment for rare bone disorders that targets the retinoic acid pathway without using retinoids

From Montreal: Find Therapeutics is developing transmembrane directed peptides - its initial testing of this platform that could have wide utility is in demyelinating diseases like MS

From Montreal: Find Therapeutics is developing transmembrane directed peptides - its initial testing of this platform that could have wide utility is in demyelinating diseases like MS

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

bottom of page